Rechercher un essai clinique
Autre(s) option(s) de recherche
60 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Essai terminé = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
CHARLY: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
ALLEMAGNE
Baden-Württemberg
MANNHEIM
Phase IIA Study on Therapy in Patients With Cutaneous T Cell Lymphoma - DE
Universitätsmedizin Mannheim
Klinik für Dermatologie, Venerologie und Allergologie
ALLEMAGNE
Nordrhein-Westfalen
MINDEN
TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma -DE-
Johannes Wesling Klinikum Minden
Universitätsklinik für Dermatologie, Venerologie, Allergologie und Phlebologie
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
RESMAIN: A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
PROMPT: A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic Mycosis Fungoides and Sezary Syndrome (Phase 2) - AT
Institution: Information not provided - AT
ESPAGNE
Cataluña
L'HOSPITALET DE LLOBREGAT
CheckMate 436: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Hematología Clínica
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
RESMAIN Study: A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
MOGAT: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) - ES
Institution: Information not provided - ES
ROYAUME-UNI
West Midlands
BIRMINGHAM
TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma-GB
University of Birmingham
University of Birmingham HQ
SUISSE
Suisse Alémanique
BERN
Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study
Inselspital Universitätsspital
Universitätsklinik für Medizinische Onkologie
ETATS-UNIS
Pennsylvania
PHILADELPHIA
A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma - US
Perelman Center for Advanced Medicine
FRANCE
ILE-DE-FRANCE
PARIS
Etude de Phase I multicentrique en ouvert évaluant IPH4102, un anticorps humanisé anti-KIR3DL2, chez des patients atteints de lymphomes cutanés à cellules T (LCCT) en rechutes ou réfractaires - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service de dermatologie
ITALIE
EMILIA ROMAGNA
BOLOGNA
A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma
Policlinico S. Orsola-Malpighi - Area S. Orsola
Dipartimento di Ematologia e Scienze Oncologiche
POLOGNE
Bydgoszcz
BYDGOSZCZ
Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.
Centrum Onkologii im. prof. F. Lukaszczyka
ROYAUME-UNI
Cambridgeshire
CAMBRIDGE
CHEMO-T: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomised phase II study - UK
University of Cambridge
Department of Medicine
ALLEMAGNE
Berlin
BERLIN
ALL-REZ BFM 2002: Multicentre Study for Children With Relapsed Acute Lymphoblastic Leukemia
Otto-Heubner-Centrum für Kinder- und Jugendmedizin
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
ALLEMAGNE
Niedersachsen
GÖTTINGEN
DSHNHL 2006-1B (ACT-2): Randomized phase III trial will evaluate the efficacy of Chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 6 courses of 2-weekly CHOP, versus standard Chemotherapy with 2-weekly CHOP alone in elderly patients with peripheral T-cell lymphomas (A-CHOP-14) - DE
Universitätsmedizin Göttingen
Klinik für Hämatologie und Medizinische Onkologie
ESPAGNE
Cataluña
BARCELONA
Immunotherapy with differential, adult, autologous, peripheral blood cells, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 specificity associated with costimulatory sequences 4-1-BB and CD3z in patients with Classical Hodgkin's lymphoma and non-Hodgkin's lymphoma T with CD30 expression - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie
ALLEMAGNE
Bayern
REGENSBURG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
ALLEMAGNE
Bayern
WÜRZBURG
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Würzburg
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE
Institution: Information not provided - DE
ALLEMAGNE
Berlin
BERLIN
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Charité - Universitätsmedizin Berlin
ALLEMAGNE
Nordrhein-Westfalen
ESSEN
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
ALLEMAGNE
Nordrhein-Westfalen
MÜNSTER
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Münster
ALLEMAGNE
Sachsen
LEIPZIG
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Etude clinique de phase I/IIa évaluant des administrations intra-tumorales (IT) répétées de BT-001 (TG6030) seul ou en combinaison avec le pembrolizumab chez des patients présentant des lésions tumorales cutanées ou sous-cutanées ou des ganglions lymphatiques facilement injectables de tumeurs solides avancées ou métastatiques - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service d'oncologie médicale
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
UNITY: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin' s Lymphoma - ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) - ES
Institution: Information not provided - ES
FRANCE
ILE-DE-FRANCE
VILLEJUIF
Étude de phase I/II d'escalade de dose de l'inhibiteur d'Histone déacétylase S 78454 administré par voie orale dans la maladie de Hodgkin, les Lymphomes malins non-Hodgkiniens, et les Leucémies Lymphoïdes Chroniques
CLCC Institut Gustave Roussy
Département d'hématologie
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders
Institution: Information not provided - IT
ITALIE
LOMBARDIA
ROZZANO
A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (>65 and <75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy
IRCCS Istituto Clinico Humanitas
U.O. Oncologia Medica ed Ematologia
ITALIE
PIEMONTE
TORINO
Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
S.C. di Ematologia
PAYS-BAS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
ROYAUME-UNI
Cambridgeshire
CAMBRIDGE
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB
Addenbrooke's Hospital
Cambridge Cancer Trials Centre
ROYAUME-UNI
Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
ROYAUME-UNI
Greater London
LONDON
UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital
Department of Haematology
ROYAUME-UNI
Greater London
UXBRIDGE
SUISSE
Suisse Italienne
BELLINZONA
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH
Ospedale Regionale di Bellinzona e Valli
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in participants 45 years or older with either a solid tumor or hematologic malignant disease who are receiving or scheduled to receive systemic anticancer therapy (independent of intent) - AT
Institution: Information not provided - AT
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Étude ouverte de phase I/II visant à évaluer la pharmacocinétique, la pharmacodynamique, la sécurité d'utilisation et l'activité anticancéreuse de l'Avelumab chez des sujets pédiatriques de la naissance à moins de 18 ans d'âge, atteints de tumeurs solides ou d'un lymphome réfractaires ou en rechute - BE
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALIE
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
Essai(s) clinique(s) multinational(aux)
ALLEMAGNE
Bayern
MARTINSRIED/PLANEGG
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PROMPT: A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic Mycosis Fungoides and Sezary Syndrome
EORTC
European Organisation for the Research and Treatment of Cancer
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment
EORTC
European Organisation for the Research and Treatment of Cancer
ETATS-UNIS
California
LOS ANGELES
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Children's Hospital Los Angeles
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
ALLEMAGNE
Hessen
DARMSTADT
ESPAGNE
Madrid
COLMENAR VIEJO
A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (coordination)
PharmaMar S.A.
Pharma Mar S.A.
ETATS-UNIS
New Jersey
SUMMIT
ETATS-UNIS
Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Institution: Information not provided - US
SUISSE
Suisse Alémanique
BASEL
An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination)
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
ESPAGNE
Madrid
COLMENAR VIEJO